Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Trends in design of FDA registrational randomized clinical trials in hematology and oncology: a 20-year cohort study.

BMJ connections. Oncology·2026

Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).

Cancer·2025

Same author

Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis.

Expert review of anticancer therapy·2025

Same author

Prevalence and Associated Factors for Depression Among Patients With Sarcoma.

JCO oncology practice·2025

Search research articles

Related Experiment Video

Updated: Jun 10, 2025

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma.

Michael J Robinson¹, Elizabeth J Davis²

¹Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA.

Current Treatment Options in Oncology

|October 17, 2024

Summary

Osteosarcoma treatment has stalled for 40 years despite advances in chemotherapy and surgery. Novel therapies like TKIs and CAR T-cells show promise but face challenges for improved patient outcomes.

Keywords:

Chimeric antigen receptor T cells Immune Checkpoint Inhibitors Immunotherapy Monoclonal antibodies Osteosarcoma Receptor tyrosine kinases Systemic therapy

More Related Videos

Author Spotlight: Standardized Herbal Decoction Protocol for Enhanced Animal Studies

Author Spotlight: Standardized Herbal Decoction Protocol for Enhanced Animal Studies

Published on: June 7, 2024

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Experiment Videos

Last Updated: Jun 10, 2025

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Author Spotlight: Standardized Herbal Decoction Protocol for Enhanced Animal Studies

Author Spotlight: Standardized Herbal Decoction Protocol for Enhanced Animal Studies

Published on: June 7, 2024

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Area of Science:

Orthopedic Oncology
Medical Oncology
Cancer Therapeutics

Background:

Osteosarcoma is the most common primary bone cancer in adolescents and adults.
Current standard of care, methotrexate, doxorubicin, and cisplatin (MAP) chemotherapy with surgery, has not improved survival in 40 years.
Metastatic osteosarcoma has a poor 5-year survival rate of 10-20%.

Purpose of the Study:

To review the current neoadjuvant standard of care for osteosarcoma.
To discuss contemporary therapeutic options beyond MAP chemotherapy.
To identify challenges and future research directions for osteosarcoma treatment.

Main Methods:

Review of current neoadjuvant standard of care (MAP chemotherapy and surgery).
Survey of contemporary therapeutic options: tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), and chimeric antigen receptor (CAR) T cells.
Analysis of challenges hindering novel treatment success.

Main Results:

The efficacy of MAP chemotherapy has plateaued, leading to persistent poor outcomes for 40 years.
Novel therapeutic strategies, including TKIs, ICIs, mAbs, and CAR T-cells, are under investigation.
Clinical trials for novel treatments have not yet yielded significant improvements in patient survival.

Conclusions:

There is a critical need for improved therapeutic strategies to overcome the treatment plateau in osteosarcoma.
Investigating and overcoming challenges associated with novel therapies is crucial for future progress.
Further research into targeted therapies and immunotherapies holds potential for advancing osteosarcoma treatment.